Vertex
As of the edition of 20 October 2026, Vertex runs 53 drugs, 9 of them marketed; it is on route A at 8 targets and on route B at 3 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 7 company names in this family.
- Alpine Immune Sciences, Inc.: acquired in 2024; successor VERTEX PHARMACEUTICALS INC
- Nivalis Therapeutics, Inc.: acquired in 2024; successor VERTEX PHARMACEUTICALS INC
- Crinetics Pharmaceuticals Inc.: acquired in 2026; successor VERTEX PHARMACEUTICALS INC
Drugs by status
| Status | Count |
|---|---|
| Marketed | 9 |
| Active | 14 |
| Went quiet | 11 |
| Stopped | 9 |
| Status not established | 10 |
| Total | 53 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Ivacaftor | Ends 2040 (patent) | 0 |
| Telaprevir | none listed | 0 |
| Tezacaftor | none listed | 0 |
| Suzetrigine | Ends 2040 (patent) | 1 |
| Elexacaftor | none listed | 0 |
| Lumacaftor | none listed | 0 |
| Vanzacaftor | none listed | 0 |
| Exagamglogene autotemcel | Ends 2035 (computed from the first US licence) | 1 |
| Paltusotine | Ends 2039 (patent) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 8 targets, route B at 3 targets.
All 11 rows on route A or B
In the product11 company-target rows on route A or B; 8 are not shown here, and no score is.
See all 11 targets where Vertex needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Digestive system: 152 trials led
- Inherited and neonatal: 141 trials led
- Lungs and airways: 126 trials led